Why Did Greenwich LifeSciences Plunge 14.64% Despite Positive Data?

On April 23, 2025, Greenwich LifeSciences, Inc. (GLSI) experienced a significant drop of 14.64% in pre-market trading, reflecting a notable decline in investor sentiment.

Recent developments have influenced Greenwich LifeSciences' stock performance. The company's price target was raised to $39 from $38 by H.C. Wainwright, maintaining a Buy rating. This adjustment was attributed to positive immune response data from its ongoing Phase 3 clinical trial, which has bolstered investor confidence in the company's prospects.

Additionally, Snehal Patel, the CEO and CFO of Greenwich LifeSciences, made a substantial stock purchase. On April 17, 2025, Patel acquired 5,400 shares of the company's common stock, demonstrating his confidence in the company's future growth and stability.